We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top tier investors such as BB Pureos Bioventures, NEA, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, Morningside Venture Investments, Jeito Capital and others.
Financed: $80M raised
New target/core pathway for fibrosis. Treatment of late-stage fibrosis, related cancers. Initially liver.
Financed: $37.5M raised
Antibody platform re-focusing IL-2 to CTLs to fuel anti-cancer immunity.
Incubating
First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach.
Financed
Tag cell populations for removal or shielding. Better, safer safe bone marrow transplants and stem cell replacement.
Stopped
Developing novel inflammasome inhibitors.
Incubating
Highly potent and specific therapies based on T cell receptor (TCR), targeting of solid tumors.
Incubating
Platform to create compartment locked biologics for higher local retention and fast systemic degradation
Incubating
A novel class of immunosuppressive therapies for autoimmune inflammatory diseases and organ transplantation
Incubating
Gene logic circuits. In-vivo multifactorial identification and killing of cancer cells.
Incubating
Bacterial mixes as microbiome therapeutics in IBD and oncology based on mixed-culture technology.
Financed: $41.5M raised
Glycomimetic platform for removing auto-antibodies in autoimmune neuropathies.
Financed: $25M raised
Novel targets that mediate endocannabinoid efficacy. Treatments for stress, anxiety etc.
Financed: $42M raised
Intracellular delivery of therapeutic payloads using bacteria, exploiting bacterial tumor targeting.
Sold
Functional ID of (neo)antigens for cancer, immunological and infectious diseases.
Financed: $16.5M raised
Cancer drug resistance platform to develop small molecules addressing non mutational mechanisms of therapy evasion.
Financed: $18.5M raised
mRNA platform for local regenerative medicine-based therapeutics.
